Spot Scanning Proton Therapy for Sinonasal Malignant Tumors
Purpose: Treatment of sinonasal malignant tumors is challenging, and evidence to establish a standard treatment is limited. Our objective was to evaluate the efficacy and safety of spot scanning proton therapy (SSPT) for sinonasal malignant tumors. Patients and Methods: We retrospectively analyzed p...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Particle Therapy Co-operative Group
2021-06-01
|
| Series: | International Journal of Particle Therapy |
| Subjects: | |
| Online Access: | https://theijpt.org/doi/pdf/10.14338/IJPT-D-20-00043.1 |
| _version_ | 1797203917063323648 |
|---|---|
| author | Koichiro Nakajima, MD Hiromitsu Iwata, MD Yukiko Hattori, MD Kento Nomura, MD Shingo Hashimoto, MD Toshiyuki Toshito, PhD Kensuke Hayashi, MS Yo Kuroda, MD Hideo Fukano, DMD Hiroyuki Ogino, MD Yuta Shibamoto, MD |
| author_facet | Koichiro Nakajima, MD Hiromitsu Iwata, MD Yukiko Hattori, MD Kento Nomura, MD Shingo Hashimoto, MD Toshiyuki Toshito, PhD Kensuke Hayashi, MS Yo Kuroda, MD Hideo Fukano, DMD Hiroyuki Ogino, MD Yuta Shibamoto, MD |
| author_sort | Koichiro Nakajima, MD |
| collection | DOAJ |
| description | Purpose: Treatment of sinonasal malignant tumors is challenging, and evidence to establish a standard treatment is limited. Our objective was to evaluate the efficacy and safety of spot scanning proton therapy (SSPT) for sinonasal malignant tumors.
Patients and Methods: We retrospectively analyzed patients with sinonasal malignant tumors (T1-4bN0-2M0) who underwent SSPT between May 2014 and September 2019. The prescription dose was typically either 60 GyRBE in 15 fractions or 60.8 GyRBE in 16 fractions for mucosal melanoma and 70.2 GyRBE in 26 fractions for other histologic subtypes. Endpoints included local control (LC), progression-free survival, overall survival (OS), and incidence of toxicity. Prognostic factors were analyzed using the Kaplan-Meier method and log-rank test.
Results: Of 62 enrolled patients, the common histologic subtypes were mucosal melanoma (35%), squamous cell carcinoma (27%), adenoid cystic carcinoma (16%), and olfactory neuroblastoma (10%). Locally advanced stages were common (T3 in 42% and T4 in 53%). Treatment-naïve tumors and postsurgical recurrent tumors accounted for 73% and 27%, respectively. No patient had previous radiotherapy. The median follow-up was 17 months (range, 6-66) for all patients and 21.5 months (range, 6-66) for survivors. The 2-year LC, progression-free survival, and OS rates of all patients were 92%, 50%, and 76%, respectively. Univariate analysis revealed histology as a prognostic factor for OS, being higher in adenoid cystic carcinoma and olfactory neuroblastoma than in other tumors. Sixteen grade ≥3 late toxicities were observed in 12 patients (19%), including 11 events resulting in visual impairment; the most common was cataract. There was 1 grade 4 toxicity, and there were no grade 5 toxicities.
Conclusion: SSPT was well tolerated and yielded good LC for sinonasal malignant tumors. Although we consider SSPT to be a leading treatment modality, further studies are required to establish its status as a standard treatment. |
| first_indexed | 2024-04-24T08:26:57Z |
| format | Article |
| id | doaj.art-6b3c7bba56aa460787d2cb9168936fb7 |
| institution | Directory Open Access Journal |
| issn | 2331-5180 |
| language | English |
| last_indexed | 2024-04-24T08:26:57Z |
| publishDate | 2021-06-01 |
| publisher | Particle Therapy Co-operative Group |
| record_format | Article |
| series | International Journal of Particle Therapy |
| spelling | doaj.art-6b3c7bba56aa460787d2cb9168936fb72024-04-16T21:47:32ZengParticle Therapy Co-operative GroupInternational Journal of Particle Therapy2331-51802021-06-018118919910.14338/IJPT-D-20-00043.1i2331-5180-8-1-189Spot Scanning Proton Therapy for Sinonasal Malignant TumorsKoichiro Nakajima, MD0Hiromitsu Iwata, MD1Yukiko Hattori, MD2Kento Nomura, MD3Shingo Hashimoto, MD4Toshiyuki Toshito, PhD5Kensuke Hayashi, MS6Yo Kuroda, MD7Hideo Fukano, DMD8Hiroyuki Ogino, MD9Yuta Shibamoto, MD101 Department of Radiation Oncology, Nagoya Proton Therapy Center, Nagoya City West Medical Center, Nagoya, Japan1 Department of Radiation Oncology, Nagoya Proton Therapy Center, Nagoya City West Medical Center, Nagoya, Japan1 Department of Radiation Oncology, Nagoya Proton Therapy Center, Nagoya City West Medical Center, Nagoya, Japan1 Department of Radiation Oncology, Nagoya Proton Therapy Center, Nagoya City West Medical Center, Nagoya, Japan2 Department of Radiology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan3 Department of Proton Therapy Physics, Nagoya Proton Therapy Center, Nagoya, Japan4 Department of Proton Therapy Technology, Nagoya Proton Therapy Center, Nagoya City West Medical Center, Nagoya, Japan5 Department of Otorhinolaryngology, Nagoya City West Medical Center, Nagoya, Japan6 Department of Oral and Maxillofacial Surgery, Nagoya City West Medical Center, Nagoya, Japan1 Department of Radiation Oncology, Nagoya Proton Therapy Center, Nagoya City West Medical Center, Nagoya, Japan2 Department of Radiology, Nagoya City University Graduate School of Medical Sciences, Nagoya, JapanPurpose: Treatment of sinonasal malignant tumors is challenging, and evidence to establish a standard treatment is limited. Our objective was to evaluate the efficacy and safety of spot scanning proton therapy (SSPT) for sinonasal malignant tumors. Patients and Methods: We retrospectively analyzed patients with sinonasal malignant tumors (T1-4bN0-2M0) who underwent SSPT between May 2014 and September 2019. The prescription dose was typically either 60 GyRBE in 15 fractions or 60.8 GyRBE in 16 fractions for mucosal melanoma and 70.2 GyRBE in 26 fractions for other histologic subtypes. Endpoints included local control (LC), progression-free survival, overall survival (OS), and incidence of toxicity. Prognostic factors were analyzed using the Kaplan-Meier method and log-rank test. Results: Of 62 enrolled patients, the common histologic subtypes were mucosal melanoma (35%), squamous cell carcinoma (27%), adenoid cystic carcinoma (16%), and olfactory neuroblastoma (10%). Locally advanced stages were common (T3 in 42% and T4 in 53%). Treatment-naïve tumors and postsurgical recurrent tumors accounted for 73% and 27%, respectively. No patient had previous radiotherapy. The median follow-up was 17 months (range, 6-66) for all patients and 21.5 months (range, 6-66) for survivors. The 2-year LC, progression-free survival, and OS rates of all patients were 92%, 50%, and 76%, respectively. Univariate analysis revealed histology as a prognostic factor for OS, being higher in adenoid cystic carcinoma and olfactory neuroblastoma than in other tumors. Sixteen grade ≥3 late toxicities were observed in 12 patients (19%), including 11 events resulting in visual impairment; the most common was cataract. There was 1 grade 4 toxicity, and there were no grade 5 toxicities. Conclusion: SSPT was well tolerated and yielded good LC for sinonasal malignant tumors. Although we consider SSPT to be a leading treatment modality, further studies are required to establish its status as a standard treatment.https://theijpt.org/doi/pdf/10.14338/IJPT-D-20-00043.1proton therapyspot scanningsinonasal cancer |
| spellingShingle | Koichiro Nakajima, MD Hiromitsu Iwata, MD Yukiko Hattori, MD Kento Nomura, MD Shingo Hashimoto, MD Toshiyuki Toshito, PhD Kensuke Hayashi, MS Yo Kuroda, MD Hideo Fukano, DMD Hiroyuki Ogino, MD Yuta Shibamoto, MD Spot Scanning Proton Therapy for Sinonasal Malignant Tumors International Journal of Particle Therapy proton therapy spot scanning sinonasal cancer |
| title | Spot Scanning Proton Therapy for Sinonasal Malignant Tumors |
| title_full | Spot Scanning Proton Therapy for Sinonasal Malignant Tumors |
| title_fullStr | Spot Scanning Proton Therapy for Sinonasal Malignant Tumors |
| title_full_unstemmed | Spot Scanning Proton Therapy for Sinonasal Malignant Tumors |
| title_short | Spot Scanning Proton Therapy for Sinonasal Malignant Tumors |
| title_sort | spot scanning proton therapy for sinonasal malignant tumors |
| topic | proton therapy spot scanning sinonasal cancer |
| url | https://theijpt.org/doi/pdf/10.14338/IJPT-D-20-00043.1 |
| work_keys_str_mv | AT koichironakajimamd spotscanningprotontherapyforsinonasalmalignanttumors AT hiromitsuiwatamd spotscanningprotontherapyforsinonasalmalignanttumors AT yukikohattorimd spotscanningprotontherapyforsinonasalmalignanttumors AT kentonomuramd spotscanningprotontherapyforsinonasalmalignanttumors AT shingohashimotomd spotscanningprotontherapyforsinonasalmalignanttumors AT toshiyukitoshitophd spotscanningprotontherapyforsinonasalmalignanttumors AT kensukehayashims spotscanningprotontherapyforsinonasalmalignanttumors AT yokurodamd spotscanningprotontherapyforsinonasalmalignanttumors AT hideofukanodmd spotscanningprotontherapyforsinonasalmalignanttumors AT hiroyukioginomd spotscanningprotontherapyforsinonasalmalignanttumors AT yutashibamotomd spotscanningprotontherapyforsinonasalmalignanttumors |